v. 13 – 2020/01

Market Executive Summary Past discussions in 2016 suggested plans to move towards medicines traceability, suggested to be in line with GS1 standards with focus on market access; however, no firm requirements have been issued and no further information has been published after 2016.
Key Dates 2016